ASCT2 and LAT1 Contribution to the Hallmarks of Cancer: From a Molecular Perspective to Clinical Translation
Вклад ASCT2 и LAT1 в основные признаки рака: от молекулярного аспекта к клинической трансляции
2021-01-08
SCID: 54.1/7deacweq
Discuss with AI
ASCT2LAT1amino acid transportershallmarks of cancermTOR activation
Figures from the paper
Abstract (AI)
The role of the amino acid transporters ASCT2 and LAT1 in cancer has been explored throughout the years. In this review, we report their impact on the hallmarks of cancer, as well as their clinical significance. Overall, both proteins have been associated with cell death resistance through dysregulation of caspases and sustainment of proliferative signaling through mTOR activation. Furthermore, ASCT2 appears to play an important role in cellular energetics regulation, whereas LAT1 expression is associated with angiogenesis and invasion and metastasis activation. The molecular impact of these proteins on the hallmarks of cancer translates into various clinical applications and both transporters have been identified as prognostic factors in many types of cancer. Concerning their role as therapeutic targets, efforts have been undertaken to synthesize competitive or irreversible ASCT2 and LAT1 inhibitors. However, JHP203, a selective inhibitor of the latter, is, to the best of our knowledge, the only compound included in a Phase 1 clinical trial. In conclusion, considering the usefulness of ASCT2 and LAT1 in a variety of cancer-related pathways and cancer therapy/diagnosis, the development and testing of novel inhibitors for these transporters that could be evaluated in clinical trials represents a promising approach to cancer prognosis improvement.
Key Findings
1
ASCT2 and LAT1 contribute to cancer cell-death resistance by dysregulating caspases and sustain proliferative signaling through mTOR activation.
2
ASCT2 is particularly implicated in regulating cellular energetics, while LAT1 is associated with angiogenesis, invasion, and metastasis.
3
Competitive and irreversible inhibitors of ASCT2 and LAT1 are under development, but JHP203 is the only reported inhibitor in a Phase 1 clinical trial.
4
Developing and clinically testing novel ASCT2 and LAT1 inhibitors is proposed as a promising strategy for improving cancer prognosis.
5
Expression of both transporters has clinical prognostic value across multiple cancer types and may support cancer diagnosis or therapy.
Research Object
The amino acid transporters ASCT2 and LAT1 in cancer
Research Subject
Their molecular and clinical roles in cancer hallmarks, including regulation of cell death resistance, proliferative signaling, cellular energetics, angiogenesis, invasion and metastasis, and their prognostic and therapeutic significance
Publication Details
Publication Date
2021-01-08
Journal
Publisher
ISSN
Cited by
66
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai3
The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health2018
The L-Type Amino Acid Transporter LAT1—An Emerging Target in Cancer2019
Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1)2017